Skip to main content

Table 1 Association of HER2 expression and clinicopathological parameters

From: The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature

Clinicopathological parameters Number of studies Number of patients OR (95% CI) P Heterogeneity
      I 2 (%) P value
Age (old vs young) 27 12,800 0.90(0.74,1.10) 0.31 62.9 0.00
Sex (male vs female) 33 15,304 1.48(1.34,1.65) 0.00 21.1 0.14
Tumor size (large vs small) 11 1614 0.83(0.64,1.07) 0.21 13.4 0.32
Tumor site (proximal vs distal) 24 12,853 1.25(1.07,1.47) 0.01 27.4 0.11
Lauren’s classification (intestinal vs diffuse) 30 13,972 3.37(2.54,4.47) 0.00 74.2 0.00
TNM stage (III+IV vs I+II) 24 12,542 1.35(1.10,1.66) 0.01 62.4 0.00
Lymph node metastasis(N+ vs N−) 27 14,075 1.26(1.14,1.41) 0.03 0.0 0.66
Differentiation grade (well vs poor) 28 9086 1.79(1.15,2.76) 0.01 86.6 0.00
Distant metastasis (M+ vs M−) 9 4427 1.91(1.08,3.38) 0.00 54.4 0.03
Lymphovascular invasion (yes vs no) 10 3957 1.30(0.86,1.95) 0.22 62.5 0.00
Neural invasion (yes vs no) 4 1361 0.58(0.24,1.37) 0.21 80.1 0.00
  1. OR odds ratio, CI confidence interval, N node, M metastasis